Castrate Resistant

Advanced Prostate

- Hormone Naive
  - Non-Metastatic
    - Non-Chemotherapy, No prior AR Targeting Agent
  - Metastatic
    - IRB# 11268: Salvage radiation + enzalutamide/placebo for recurrent prostate cancer

- Incomplete Response to Hormone Therapy
  - No Trials Currently Available
    - IRB# 9892: Phase III study comparing ADT + Bicalutamide to ADT + TAK-700

- Non-Metastatic
  - No Trials Currently Available
    - IRB# 9259: Phase II study involving enzalutamide and biopsy for research

- Non-Chemotherapy, No prior AR Targeting Agent
  - IRB# 11025: Phase II study of pembrolizumab after progression on enzalutamide
  - IRB# 110241: Phase II study involving enzalutamide and biopsy for research

- Metastatic
  - IRB# 11025: Phase II study of docetaxel + dendritic cell vaccine or placebo
  - IRB# 10479: Phase III study of docetaxel + enzalutamide

- 1st Line Chemotherapy
  - IRB# 10241: Phase II study involving enzalutamide and biopsy for research

- Post-Chemotherapy
  - IRB# 11227: Phase II study of cabazitaxel + enzalutamide

- Supportive Care/Biomarker
  - IRB# 9204: Stand Up To Cancer Biopsy for research

New Trials Coming Soon

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

03/31/2017

http://www.ohsu.edu/research/key_by_institute.php